Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose radiotherapy plus retilrafusp alfa and chemotherapy versus retilrafusp alfa plus chemotherapy as neoadjuvant therapy for resectable locally advanced ESCC
ChiCTR2600133477Phase 2Not yet recruiting
- Sponsor
- Harbin Medical University Cancer Hospital
- Start
- Oct 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of retlirafusp alfa in Esophageal Squamous Cell Carcinoma (ESCC) (2 cohorts), sponsored by Harbin Medical University Cancer Hospital. Primary endpoint: Pathological complete response rate. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
retlirafusp alfa
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2600133477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600133477.